<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402713</url>
  </required_header>
  <id_info>
    <org_study_id>GC1107_P2/3</org_study_id>
    <nct_id>NCT01402713</nct_id>
  </id_info>
  <brief_title>To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children</brief_title>
  <official_title>Randomized, Double Blind, Multicenter, Phase II/III Study to Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness(immunogenicity) and safety of&#xD;
      'GC1107' administered intramuscularly in healthy children&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double blind, multicenter, phase Ⅱ/Ⅲ study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Step I-the seroprotection rate of diphtheria and tetanus</measure>
    <time_frame>28 days</time_frame>
    <description>Number of participants after vaccination as a measure of the effectiveness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Step II-to assess noninferior of diphtheria and tetanus</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>StepI-GMT of diphtheria and tetanus</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step I-safety assessment-solicited adverse event</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step II-GMT of diphtheria and tetanus</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step II-safety assessment-solicited adverse event</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step II- Boosting response of diphtheria and tetanus</measure>
    <time_frame>28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">311</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>GC1107-T5.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage: 0.5ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC1107-T7.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage: 0.5ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD_PUR INJ /SK Td vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The name: step 1(phase 2)-SK Td vaccine step 2(phase 3)-TD_PUR INJ Dosage: 0.5ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC1107</intervention_name>
    <description>GC1107-T5.0: low dose, GC1107-T7.5: high dose</description>
    <arm_group_label>GC1107-T5.0</arm_group_label>
    <arm_group_label>GC1107-T7.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TD_PUR INJ / SK Td vaccine</intervention_name>
    <description>step 1(phase 2)-TD_PUR INJ step 2(phase 3)-SK Td vaccine</description>
    <arm_group_label>TD_PUR INJ /SK Td vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy Korean children(age: 10 ~ 17)&#xD;
&#xD;
               -  In the case of step1 (for step 1) 11~12 years&#xD;
&#xD;
          -  who got the basic vaccination(5 times vaccination of diphtheria and tetanus until 6&#xD;
             years old.)&#xD;
&#xD;
          -  Subjects willing to provide written informed consent and able to comply with the&#xD;
             requirements for the study or informed consent was obtained from the subject's legal&#xD;
             guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with antitoxin of diphtheria and tetanus ≥1.0IU/mL (ELISA)&#xD;
&#xD;
               -  only applicable in step 1&#xD;
&#xD;
          -  subjects who have not recovered from the acute disease within 2 weeks&#xD;
&#xD;
          -  who has experienced the temporary platelet decrease or has the medical history of&#xD;
             neurologic complication&#xD;
&#xD;
          -  who has the medical history of allergic disease related to the components of&#xD;
             investigational drug&#xD;
&#xD;
          -  who has experienced the severe adverse events for the diphtheria and tetanus&#xD;
             vaccination&#xD;
&#xD;
          -  who got the vaccination of diphtheria and tetanus within 5 years&#xD;
&#xD;
          -  who has not recovered from the acute disease within 2 weeks&#xD;
&#xD;
          -  who got the treatment of blood product within 3 months&#xD;
&#xD;
          -  who got the immunoglobulin should have the wash-out period&#xD;
&#xD;
          -  who be infected from the diphtheria and tetanus&#xD;
&#xD;
          -  Subjects who are scheduled to participate in other clinical trial studies during the&#xD;
             study.&#xD;
&#xD;
          -  Current participation in a clinical study involving any other drugs including vaccine&#xD;
             within 4 weeks of enrollment of the study vaccine.&#xD;
&#xD;
          -  Subjects who have participated in any other clinical trials within 4 weeks of the&#xD;
             administration of the study&#xD;
&#xD;
          -  Subject who have received adrenocortical hormones or immunosuppressive drug within&#xD;
             4weeks of enrollment&#xD;
&#xD;
          -  Subjects with a history of chronic disease obstacles to the study.&#xD;
&#xD;
          -  Subjects who have episode of acute febrile (at least 37.5) after injection of vaccine&#xD;
             during the study&#xD;
&#xD;
          -  Subject who have plan of operation during the study.&#xD;
&#xD;
          -  Individuals with other clinically significant medical or psychological condition who&#xD;
             are considered by the investigator to be ineligible for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JinHan Kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seol St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The catholic university of Korea, Seoul st. mary's hospital</name>
      <address>
        <city>Banpo-dong</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <last_update_submitted>January 23, 2015</last_update_submitted>
  <last_update_submitted_qc>January 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

